Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis (Q79747223)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

title

Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

experimental autoimmune encephalomyelitis

25 December 2019

main subject

1 reference

Ritika Jaini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Drew Hannaman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Justin M Johnson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Robert M Bernard

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Cengiz Z Altuntas

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Maida M Delasalas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Pavani Kesaraju

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Alain Luxembourg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Claire F Evans

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Vincent K Tuohy

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

16 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

416-422

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Multiple sclerosis: side effects of interferon beta therapy and their management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Cloning and expression of murine IFN beta and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

IFN-beta gene transfer into the central nervous system using bone marrow cells as a delivery system.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

High-efficiency gene transfer into skeletal muscle mediated by electric pulses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

High-efficiency growth hormone-releasing hormone plasmid vector administration into skeletal muscle mediated by electroporation in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Electroporation for gene transfer to skeletal muscles: current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Controlled release systems for DNA delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Regulatable gene expression systems for gene therapy applications: progress and future challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Inducible control of transgene expression with ecdysone receptor: gene switches with high sensitivity, robust expression, and reduced size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.04.009

10.1016/J.YMTHE.2006.04.009

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16782409%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference